Pharmaceuticals UK

UK Sickle Cell Disease Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

UK Sickle Cell Disease Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UK · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $90.9 Mn Placeholder estimate
Estimate 2025 $105.3 Mn 2.7% of the global market
Projected 2034 $394.2 Mn 274.4% Adds $288.9 Mn over 9 forecast years
CAGR 2025–2034 15.8% Faster than 82% of 180 Pharmaceuticals markets here
Key players 5
  • UK is 2.7% of the global market.
  • In Europe, the largest is Germany at $126.8 Mn.
  • Fastest growing: Russia at 18.1% a year.
  • UK ranks 3rd of 6 by size in Europe.

Market size projection

UK

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$288.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Sickle Cell Disease Therapeutics Market market size by year, UK
YearMarket sizeChange that yearSince 2025
2024 (estimate) $90.9 Mn — —
2025 (base) $105.3 Mn +$14.4 Mn —
2026 (forecast) $121.9 Mn +$16.6 Mn +15.8%
2027 (forecast) $141.2 Mn +$19.3 Mn +34.1%
2028 (forecast) $163.5 Mn +$22.3 Mn +55.3%
2029 (forecast) $189.3 Mn +$25.8 Mn +79.8%
2030 (forecast) $219.2 Mn +$29.9 Mn +108.2%
2031 (forecast) $253.8 Mn +$34.6 Mn +141.1%
2032 (forecast) $293.9 Mn +$40.1 Mn +179.2%
2033 (forecast) $340.4 Mn +$46.4 Mn +223.3%
2034 (forecast) $394.2 Mn +$53.8 Mn +274.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

UK Sickle Cell Disease Therapeutics Market Analysis at a glance
Market size, 2025$105.3 Mn placeholder estimate
Forecast, 2034$394.2 Mn placeholder estimate
Growth (CAGR), 2025–203415.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledSickle Cell Disease Treatment
SegmentsTreatment, age and end user (see all)
Key playersVertex Pharmaceuticals, bluebird bio, Pfizer Inc., Novartis AG, Novo Nordisk A/S (see all)
Regulator in the UKMHRASource: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
Active clinical trials17 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The UK Sickle Cell Disease Therapeutics Market Analysis Executive Summary

Sickle cell disease therapeutics include gene therapies, gene editing and medicines that reduce pain crises and organ damage.

Key segments of the sickle Cell Disease Therapeutics market include treatment (Gene Therapy, Gene Editing and Hydroxyurea) and age (Pediatric and Adult).

Bar chart: UK Sickle Cell Disease Therapeutics market size, 2024–2034, placeholder estimates. $90.9 Mn in 2024, $105.3 Mn in 2025 and $394.2 Mn in 2034, 15.8% CAGR.
UK Sickle Cell Disease Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

UK Sickle Cell Disease Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the sickle Cell Disease Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the sickle Cell Disease Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the sickle Cell Disease Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Sickle Cell Disease Therapeutics Market in UK

The sickle Cell Disease Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Sickle Cell Disease Therapeutics Market in UK

Sickle Cell Disease Therapeutics in the UK: rules, payment and research

The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK.⁠[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.⁠[2] ClinicalTrials.gov lists 17 studies on Sickle Cell Disease Therapeutics that are recruiting, active or about to start in the UK.⁠[3]

[1] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[2] National Institute for Health and Care Excellence. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for sickle Cell Disease Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UK.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Sickle Cell Disease Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Sickle Cell Disease Therapeutics in context

The UK compared

  • Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 5th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 19.7% of people (2025). World: 10.4% of people (2025). 5th highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Sickle Cell Disease Therapeutics market in the UK?
Placeholder estimate: about $105.3 Mn in 2025, rising to about $394.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Sickle Cell Disease Therapeutics market in the UK growing?
Placeholder estimate: about 15.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Sickle Cell Disease Therapeutics market report cover?
The report splits the market by treatment (Gene Therapy, Gene Editing, Hydroxyurea, Disease-Modifying Drugs), age (Pediatric, Adult) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Sickle Cell Disease Therapeutics market?
Key players include Vertex Pharmaceuticals, bluebird bio, Pfizer Inc., Novartis AG and Novo Nordisk A/S.
What is driving the Sickle Cell Disease Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the sickle Cell Disease Therapeutics market.
Who regulates Sickle Cell Disease Therapeutics in the UK?
The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK. Source: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in the UK?
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
How many clinical trials on Sickle Cell Disease Therapeutics are running in the UK?
17 studies are recruiting, active or about to start in the UK, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
How much research is published on Sickle Cell Disease Therapeutics?
PubMed lists 3,466 papers on Sickle Cell Disease Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in UK

See all

Related on rare diseases and anemia

See the topic